
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing lorazepam, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Lorazepam is a Schedule IV controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing lorazepam are listed in tablet, injection, capsule, liquid, concentrate and solution forms. No finished lorazepam product of any kind is listed in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Lorazepam is a Schedule IV benzodiazepine, commonly compounded into oral liquids and sublingual troches, often in combinations.
Lorazepam is a benzodiazepine. It binds a site on GABA-A receptors in the brain and strengthens the calming effect of GABA, the nervous system's main inhibitory messenger, which reduces anxiety and promotes sedation. Manufactured products include Ativan and generic lorazepam tablets, FDA-approved for anxiety disorders and short-term relief of anxiety symptoms including anxiety with depressive symptoms, plus lorazepam oral concentrate and injection, which StatPearls lists for anxiety-related insomnia, preanesthetic sedation and status epilepticus. Lorazepam is a federally controlled substance in Schedule IV. A prescriber might order lorazepam compounded when a patient needs a liquid or sublingual form in a strength or vehicle not manufactured, a preparation free of propylene glycol, or a combination with other ingredients. Compounded preparations are not FDA-approved and require a prescription.
Lorazepam carries an FDA boxed warning with three parts: combining it with opioids, including many prescription cough and pain medicines, can cause profound sedation, breathing failure, coma and death; it can be abused and lead to addiction and overdose; and continued use causes physical dependence, so stopping suddenly or cutting the dose quickly can trigger life-threatening withdrawal, including seizures. Any change should be a gradual taper planned with your prescriber. Do not use lorazepam if you are allergic to benzodiazepines or have acute narrow-angle glaucoma. Alcohol, sedatives, antipsychotics and clozapine add to its depressant effects; valproate and probenecid raise its levels. People with sleep apnea, COPD, severe liver disease, depression or a history of substance use need extra caution, and older adults are more sensitive. Use late in pregnancy can cause sedation and withdrawal in newborns. Lorazepam reaches breast milk in low amounts; LactMed reports no adverse effects at usual doses, with infants watched for sedation and poor feeding. Common side effects are drowsiness, dizziness, weakness and unsteadiness. Talk to your prescriber or pharmacist about any side effect that concerns you.
Lorazepam is a benzodiazepine that potentiates GABA-A mediated chloride conductance. Oral absolute bioavailability is about 90% with peak plasma levels around 2 hours; protein binding is about 85%; elimination half-life is about 12 hours for parent drug and 18 hours for the inactive glucuronide. Metabolism is direct glucuronidation without cytochrome P450 involvement, and the conjugate is renally excreted. Labeled indications: Ativan tablets for anxiety disorders and short-term anxiety relief, with the injection labeled for status epilepticus and preanesthetic use per StatPearls. Beyond the label, prescribers have ordered lorazepam for chemotherapy-associated nausea and vomiting (including sublingually), alcohol withdrawal, rapid tranquilization of agitation, catatonia, delirium and vertigo (StatPearls). Dosing and taper schedules are per prescriber. Monitor respiratory status, sedation, blood pressure and heart rate; the label recommends periodic blood counts and liver function tests with long-term therapy, and StatPearls adds propylene glycol toxicity markers with high-dose parenteral use. Lorazepam is a Schedule IV controlled substance. Under federal DEA rules, electronic prescribing of controlled substances is an option, not a mandate; CMS applies a prescriber-level compliance threshold for Medicare Part D controlled-substance prescriptions, and a number of states mandate e-prescribing.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)